Kineret (Anakinra) - Drug Interactions, Contraindications, Overdosage

DRUG INTERACTIONS

No drug-drug interaction studies in human subjects have been conducted. Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret® when the two agents were administered together. In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret® and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%) (see also WARNINGS). Two percent of patients treated concurrently with Kineret® and etanercept developed neutropenia (ANC < 1 × 10⁹/L).

OVERDOSAGE

There have been no cases of overdose reported with Kineret® in clinical trials of RA. In sepsis trials no serious toxicities attributed to Kineret® were seen when administered at mean calculated doses of up to 35 times those given patients with RA over a 72-hour treatment period.

CONTRAINDICATIONS

Kineret® is contraindicated in patients with known hypersensitivity to E coli -derived proteins, Kineret®, or any components of the product.